EXN407
Diabetic Retinopathy / Diabetic Macular Oedema
Phase 2Active
Key Facts
About Exonate
Exonate is a clinical-stage biotech pioneering a first-in-class, topical therapy for retinal vascular diseases. Its lead asset, EXN407, is a small molecule SRPK1 inhibitor designed as an eye drop to treat diabetic retinopathy and diabetic macular oedema by influencing VEGF alternative splicing. Having completed a Phase Ib/IIa trial, the company is preparing for a Phase IIb trial in 2026, positioning itself to address a significant unmet need for non-invasive treatments. Founded in 2013 as a university spin-out, Exonate is a private, well-funded company with strong scientific foundations and advisory support.
View full company profile